Anumana wins FDA clearance for ECG-AI algorithm
Related Articles
Anumana Makes Educated Inferences in Heart Failure
Anumana was founded in 2021 as the culmination of a joint effort between the Mayo Clinic and nference, an early entrant to the field of machine learning for cardiology-focused clinical…February 01, 2026
Cardiology’s AI Moment: Anumana’s Top Insights from ACC.25
#TeamAnumana wrapped up three incredible days of exploring cardiovascular science in the Windy City at the American College of Cardiology’s Annual Scientific Session. ACC.25 brought together thousands of cardiologists, investigators,…April 22, 2025
Anumana’s AI tool for pulmonary hypertension gets FDA breakthrough status
Medical Device Network: Anumana has received US Food and Drug Administration (FDA) Breakthrough Device Designation for its artificial intelligence (AI)-enhanced, electrocardiogram (ECG)-based Pulmonary Hypertension (PH) Early Detection Algorithm. The accurate,…May 24, 2022
Anumana Receives First and Only FDA Clearance for ECG-AI Cardiac Amyloidosis Algorithm Using a Standard 12-Lead ECG
CAMBRIDGE, Mass., April 8, 2026—Anumana, Inc., a leader in cardiovascular AI, today announced U.S. Food and Drug Administration (FDA) clearance of its ECG-AI® algorithm for cardiac amyloidosis (CA) – the…April 08, 2026